News
Rhapsido is first drug cleared for chronic hives disorder SD
Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.
News
European biotech leaders say optimism is returning
Senior figures in European biopharma think dealmaking and M&A will increase in the region, and could be helped by US policy uncertainties.
News
Click claims FDA okay for first-in-class schizophrenia DTx
Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.
News
UK backs all health AI proposals in commission report
The UK will accept all 44 proposals made in a recent report on using AI tools in the NHS, including continuous monitoring after deployment.
Market Access
Beyond Market Access: Why healthcare-system understanding is...
Healthcare-system literacy, and the ability to contribute to system shaping, must become part of how healthcare leaders make decisions.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
